Introduction
============

Axonal regeneration is a fundamental step in the process of recovering from spinal cord injury (SCI). However, the axons in the adult central nervous system (CNS) cannot regenerate easily, which primarily causes the lack of adequate restorative therapy for the SCI so far. Several attempts have been made to promote regeneration, and some advances have been obtained. Importantly, these attempts appear to be the applications of certain extensively revealed mechanisms of brain development. Although the axons cannot regenerate easily in an adult brain, in the developing brain, differentiating neurons elongate the axons easily to very distal areas; this information is of utmost importance and is required to be considered post SCI. What is the difference between the ability of elongating the axons in the adult and developing brain? Understanding the mechanism of tremendous axonal elongation and navigation during development and the differences between the environments of adult and developing CNS has provided us with important clues for succeeding in regenerating axons after brain injuries. Although several allusions for the therapy have also been brought by the comparison between the peripheral nervous system (PNS) and the CNS because axons can regenerate in the former system but not in the latter, in this review, we will focus on and compare the differences between the adult and developing brain. We have briefly summarized the differences discussed in this review in [Figure 1C](#f1-btt-2-253){ref-type="fig"}. From this view, we can consider how the recent concepts and strategies for regenerating axons in the adult CNS have emerged and can be developed. Although several excellent reviews have yet described the importance of the relation of regenerative therapy with the developmental mechanisms ([@b126-btt-2-253]; [@b56-btt-2-253]), we will overview the whole aspects of its relations as much as possible with recent reports, and will emphasize that collaboration with developmental and clinical neuroscience is more needed.

Axonal regeneration in the developing brain
===========================================

Many earlier reports indicate that the axons in the early postnatal spinal cord can regenerate more easily after an injury compared to those in an adult ([Figure 1](#f1-btt-2-253){ref-type="fig"}: [@b11-btt-2-253]; [@b9-btt-2-253]; [@b43-btt-2-253]). This finding provides two main important suggestions. First, early brain tissue possesses favorable factors and environment for axonal growth, and the second, younger neurons themselves have a greater capacity for outgrowth than adult neurons. The first suggestion is a well-accepted concept, and many inhibitory factors in the adult brain have been identified up till now. We have reviewed these factors in the coming chapters; however, the important point is that understanding the favorable environment for axonal growth in the developing brain may generate a new approach in the designing of a therapy for SCI. Indeed, in many classical experiments, embryonic spinal cord was transplanted in the lesion site of the postnatal and adult spinal cord ([@b14-btt-2-253], [@b15-btt-2-253]; [@b64-btt-2-253]). In the early postnatal case, injured axons demonstrated immense regeneration passing through the transplanted embryonic tissue. In the adult case, axons could regenerate slightly but not dramatically. This also supports the abovementioned two suggestions, that early tissue is favorable for axonal growth, and younger neurons may possess a greater capacity of growth. It may be clear that younger neurons or certain types of neurons possess a much higher ability of elongating axons compared to other neurons, as suggested by the reports indicating that transplanted embryonic cortical neurons in the injured cortex can extend the axons even through the adult spinal cord ([@b48-btt-2-253]), and that neurons in different mouse strains have different regenerative abilities after SCI ([@b34-btt-2-253]). However, many of the recent approaches have partially succeeded in regenerating axons by suppressing the inhibitory cues in the adult brain, suggesting that even the adult neurons have the ability to re-elongate axons. From this view, generating a favorable environment for axonal growth in the injured site should be one of the important goals for establishing therapeutic interventions.

Axonal network formation by guidance molecules in the developing brain
======================================================================

We should first understand how the complicated and precise axonal network is formed in the developing brain. During development, several steps are required to form a complex structure and for the functioning of the brain. First, undifferentiating neural stem cells or progenitor cells proliferate extensively around the ventricle called ventricular zone to reserve a large number of neurons and glial cells for the future adult brain. Next, some of these cells start migrating to specific areas and differentiating into neurons. After reaching the final position, the neurons start projecting the axons to the target area. In many cases, the axons are facilitated to pass through specific routes and targeted to specific areas. This process is very surprising because this navigation is quite precise, and in some cases, the neurons project the axons to a great distance from the cell bodies. Since 1990's, the mechanism of this precise navigation has been revealed by various studies identifying the axonal guidance molecules. Netrin, Ephrin, Semaphorin, and Slit are the representative guidance molecules (for review [@b61-btt-2-253]). *In vitro* culture system and the analyses from knockout mice have clearly revealed that these molecules have an important role in navigating axons in the developing brain. For example, corticospinal tract (CST), the main tract connecting the sensorimotor cortex to the spinal cord for regulating the motor function ([Figure 1](#f1-btt-2-253){ref-type="fig"}), is also navigated by these molecules. In the first step, Sema3A expressed in the upper layers of the cortex repulses the axons of neurons in the deeper layer (layer V in the future) to the deeper white matter ([@b109-btt-2-253], [@b110-btt-2-253]). Slit2 then repulses the axons after passing the internal capsule, for projecting the specific route into the cerebral peduncle ([@b4-btt-2-253]). After having passed the cerebral peduncle, most of the fibers cross the midline and go through to the contralateral side. It is indicated that Netrin and its receptors, Dcc and Unc5H3 contribute to this decussation ([@b42-btt-2-253]). While passing the spinal cord, Ephrin-B3 repulses the CST not to cross the midline ([@b79-btt-2-253]; [@b159-btt-2-253]).

Recent reports have demonstrated other important molecules responsible for guiding axons, morphogens. Morphogens -- such as Sonic hedgehog (Shh), Fibroblast growth factor (Fgf), Bone morphogenetic protein (Bmp), and Wnts -- are the signaling molecules that diffuse and establish a gradient in the embryonic tissues. This gradient signal plays a crucial role in arealizing the tissues by changing the cells from single type to heterogeneous populations. These molecules play a similar role in the developing CNS. The famous example is that of the developing spinal cord in which Shh, which is expressed in the most ventral place called floor plate, is diffused dorsally and establishes a gradient concentration. As a result, several clusters of neuronal populations are generated in the ventral spinal cord depending on the concentration of Shh ([@b65-btt-2-253]). Intriguingly, recent papers have indicated that these morphogens regulate not only the specification of tissue areas and cell population, but also navigate the axons (for review [@b27-btt-2-253]). Again, CST passes through the spinal cord up to a long distance mainly in the first postnatal week in rodents ([@b50-btt-2-253]; [@b68-btt-2-253]). Interestingly, developing CST expresses Ryk, one of the Wnts receptors, and is pushed down by Wnts signals in the spinal cord after decussation ([@b86-btt-2-253]). Wnt1 and 5a are expressed in a rostral to caudal gradient that repulses the CST into lower levels. Thus, CST can be guided for a long distance to the final targets by Wnts signaling.

One ultimate strategy for facilitating definite regeneration after the SCI may be to reconstruct these guidance cues in precise positions spatially and temporally like in the developing brain. [@b69-btt-2-253] showed that injured CST in adult rats could regenerate by the local application of cervical spinal cord extracts which were harvested at the time that developing CST axons reached this spinal cord level. On the other hand, the injured axons could not regenerate when spinal cord extracts were harvested at younger or older age. This data implied that specifically organized expression of guidance molecules seen in the development is also optimal for regeneration. It is known, however, that some of these guidance molecules are still expressed in the adult developed brain in a different manner or are abnormally re-expressed at the lesion site. This appears to make the precise reconstruction of guidance cues difficult. In addition, some of these molecules are reported to suppress the regeneration of injured axons. Alternatively, recent researches have partly succeeded in promoting regeneration by suppressing the expression of these guidance molecules. We will focus on this issue in the later chapters.

Guiding cells that facilitate axonal network formation in the developing brain and their transplantation
========================================================================================================

Besides the axon guidance molecules, certain types of specific guiding cells navigate the axons in the developing brain. These cells were reported earlier as "guidepost cells" in the embryonic limb bud of grasshopper ([@b10-btt-2-253]), and in the following papers, several other types of navigating cells were identified in the corpus callosum ([@b132-btt-2-253]; [@b131-btt-2-253]), olfactory tract ([@b122-btt-2-253]), and thalamocortical axons ([@b91-btt-2-253]) of the developing rodent brain. Although the existence of guiding cells in the developing CST is also speculated from the observation of immature astrocytes discovered in the route of CST in early postnatal days ([@b71-btt-2-253]), unfortunately, there are no clear evidences regarding their role in guiding axons.

As developmentally, early brain tissues possess a favorable environment for axonal growth, implanting fetal nerve tissue may be a simple way of promoting regeneration after SCI. However, obtaining this tissue is extremely difficult, thus rendering its implantation for clinical therapy rather questionable. The next strategy is to transplant guiding cells specific to the axons in the spinal cord; however, as mentioned earlier, specific guiding cells for the CST or other axons in the spinal cord have not been identified yet. Hence, the ongoing approach is to transplant guiding or supportive cells that can be obtained from other parts of the body. Historically, two types of cell have mainly been attempted for conducting transplantation: the peripheral nerve (Schwann cells) ([@b118-btt-2-253]; [@b29-btt-2-253]; [@b141-btt-2-253]) and olfactory ensheathing glial cells (OEG) ([@b88-btt-2-253]; [@b114-btt-2-253]). These approaches were not designed from the mechanisms of developmental processes; rather, they were developed from the mechanism of regeneration and axonal outgrowth in the adult brain. Axons of PNS can regenerate more easily than those of CNS, raising the possibility that peripheral nerves or Schwann cells act as favorable substrates for axonal growth. OEGs are the specialized glial cells ensheathing olfactory axons of neurosensory cells in the olfactory epithelium. Neurosensory cells (and their axons, olfactory axons) are continuously replaced and newly formed in the adult, suggesting that OEGs support axonal outgrowth. These transplanted cells bridge the lesion site after SCI and, to a certain extent, effect regeneration and functional recovery. These experiments may provide us a new insight in to establishing therapeutic methods from the basic research on brain development: discoveries and identification of guiding cells in the developing brain may open a new strategy to promote regeneration.

Distinct tissue responses in young and adult injured CNS: the role of glial cells
=================================================================================

One of the points of differences between adult and developing brain is that adult CNS includes not only neurons but also a large number of matured glial cells. These cells are clearly activated in the injured site to repair the tissue, which appears to affect the outgrowth of injured axons.

Astrocytes are the cells that are activated after the injury and form a glial scar to repair the injured tissue. Glial scar formation is an important process for tissue repair. Conditional and selective ablation of activated astrocytes after SCI delays the repair process and caused motor deficits ([@b40-btt-2-253]). Conditional ablation of astrocytic activation using Stat3 conditional knockout model also diminishes the recovery ([@b104-btt-2-253]). These reports indicate that a glial scar plays an important role in tissue repair by protecting the neighboring intact tissues from excessive degeneration, inflammation, demyelination, etc. Unfortunately, although the glial scar is a key contributor to repair, it simultaneously inhibits axonal regeneration ([@b120-btt-2-253]). An important factor that suppresses the regeneration expressed by astrocytes is chondroitin sulfate proteoglycans (CSPGs) ([@b95-btt-2-253]; [@b67-btt-2-253]; [@b143-btt-2-253]). CSPGs are glycoproteins within extracellular matrices that function as barriers that inhibit the penetration of regenerating axons into the lesion sites. By either treating chodroitinase ABC, which is the bacterial enzyme that digests CSPGs, or by using transgenic mice that express chodroitinase ABC in astrocytes, it was possible to promote regeneration after SCI ([@b13-btt-2-253]; [@b24-btt-2-253]); although, functional recovery was not achieved in transgenic mice. In the developing brain, astrocytes are generated from neural progenitor cells in the later period of development compared with neurons ([@b144-btt-2-253]). Thus, astrocytic responses do not occur in early embryonic brain injury ([@b145-btt-2-253]). SCI in early postnatal days activates astrocytes but no more remarkably than in adults ([@b7-btt-2-253]; [@b43-btt-2-253]) possibly due to the lower number of astrocytes and lesser extent of maturation. Interestingly, although CSPGs are basically considered as barriers to axonal elongation in the developing brain ([@b135-btt-2-253]; [@b74-btt-2-253]), they are not upregulated remarkably in the young reactive astrocytes after an injury ([@b95-btt-2-253]; [@b37-btt-2-253]). It may imply that axons in a younger brain can regenerate easily due to the lack of inhibitory factors from activated astrocytes. Moreover, others reported that reactive astrocytes in the younger brains could be permissive for or promote axonal growth ([@b120-btt-2-253]; [@b5-btt-2-253]). This suggests that there may be different types of astrocytes, particularly, an inhibitory and permissive type for axonal growth as indicated even in the amphibian which has a greater potential for regeneration ([@b117-btt-2-253]; [@b134-btt-2-253]). The permissive type also looks like a similar phenotype as seen in several regions of the developing brain as guiding cells (see previous chapter). Thus, understanding the mechanism of astroglial activation into different types and implanting supportive astrocytes into the lesion may establish a new approach to promote axonal outgrowth ([@b30-btt-2-253]).

Although, the reason for which scar formation is required to block regeneration is not clear, at least, the most important role of the scar should be finishing and enclosing the repairing (inflammatory) response to protect from neighboring intact CNS tissue. Thus, scar response should not be eliminated from the list of possible strategies that can be considered for the therapy. Instead, because scar inhibits the outgrowth of axons, completing the repair process speedily and compacting the scar to as small as possible, or deleting specific molecules that suppresses regeneration but not scar formation, should be the considered approach.

Oligodendrocytes are the glial cells that are involved in myelination. It is widely accepted that these cells (or its components and debris) also inhibit axonal regeneration post SCI. Earlier experiments performed by Schwab's group revealed that in the rats in which oligodendrocytes (and myelin) are deleted, axonal regeneration after SCI is promoted more than in control rats ([@b123-btt-2-253]). Subsequently, they generated a monoclonal antibody known as IN-1 that recognizes myelin-associated inhibitory proteins, and revealed that treatment using this antibody promotes axonal regeneration ([@b125-btt-2-253]; [@b16-btt-2-253]). Then, Nogo was identified as the inhibitory protein that is recognized by IN-1 ([@b28-btt-2-253]; [@b53-btt-2-253]; [@b113-btt-2-253]). Myelin-associated glycoprotein (MAG) ([@b101-btt-2-253]; [@b96-btt-2-253]), and oligodendrocyte myelin protein (OMgp) ([@b77-btt-2-253]; [@b150-btt-2-253]) were also identified as the inhibitory proteins for axonal outgrowth. Surprisingly, all of these three inhibitory proteins exert their inhibitory function through one common receptor, Nogo-66 receptor (NgR) ([@b46-btt-2-253]; [@b35-btt-2-253]; [@b89-btt-2-253]; [@b150-btt-2-253]) and its receptor complex p75 ([@b150-btt-2-253]; [@b154-btt-2-253]; [@b155-btt-2-253]), Lingo-1 ([@b97-btt-2-253]), and TROY ([@b105-btt-2-253]; [@b130-btt-2-253]) (for review, [@b157-btt-2-253]). Extensive studies using Nogo antibody ([@b125-btt-2-253]; [@b16-btt-2-253]) and Nogo knockout mice ([@b75-btt-2-253]; [@b133-btt-2-253]) and NgR ([@b76-btt-2-253]) have demonstrated that this is one of the critical factors inhibiting regeneration in SCI; although, several reports were unable to prove similar roles of Nogo and NgR as inhibitors ([@b162-btt-2-253], [@b163-btt-2-253]). Similarly, MAG ([@b8-btt-2-253]), p75 ([@b136-btt-2-253]) deficient mice do not undergo regeneration after SCI, but treatment using Lingo-1 antagonist promotes axonal sprouting ([@b66-btt-2-253]). Several controversial results regarding the role of myelin-associated proteins in regeneration suggest that the inhibitory cues may affect the injured axons through more varieties of molecules and through complicated mechanisms.

Myelination starts later in CNS development after P14 in the spinal cord of the rodents ([@b128-btt-2-253]; [@b71-btt-2-253]; [@b60-btt-2-253]). This may also imply that the strong capacity of regeneration in younger animals is achieved due to lesser amounts of myelin components, although Nogo is expressed early in postnatal period by neurons ([@b62-btt-2-253]). Interestingly, less amount of myelin can also enable the developing axons to display the plastic changes (plasticity) during the early postnatal period for learning and adapting to their external environment. This fact could also lead to understanding the mechanism that promotes plasticity after an adult CNS injury. Indeed, some studies succeeded in promoting plasticity after the injury by modifying myelin-components. We will discuss this issue in the next section.

Microglia is the last glial cell that is believed to be originated from mesenchymal lineage (monocyte or myeloid) ([@b26-btt-2-253]), which is different from other glial cells that are generated from neural progenitor cells ([@b144-btt-2-253]). One interesting aspect regarding microglia is that this cell has different phases or types that are beneficial and detrimental for axons. One direct evidence that microglia is an inhibitory factor for regeneration is that treatment using minocycline, an inhibitor of activation of microglia, promotes recovery by decreasing the dieback of CST and cell death of oligodendrocytes ([@b138-btt-2-253]; [@b41-btt-2-253]; [@b161-btt-2-253]). Depletion of hematogenous macrophages also promotes partial recovery ([@b111-btt-2-253]). Since minocycline has an additional neuroprotective effect ([@b160-btt-2-253]), a selective ablation of microglial cells using transgenic mice ([@b81-btt-2-253]) may provide us with more convincing results regarding the actual role of microglia in SCI. The beneficial aspects of these cells are suggested from the fact that coculturing microglia with neurons can promote the extension of neurites ([@b102-btt-2-253]; [@b25-btt-2-253]; [@b12-btt-2-253]). Indeed, microglia express neurotrophic factors ([@b38-btt-2-253]; [@b36-btt-2-253]). One report suggested that later activation of microglial cells *in vivo* by treatment of GM-CSF after SCI facilitates regeneration possibly due to BDNF expression by microglia ([@b12-btt-2-253]). Some other studies also succeeded in promoting recovery by transplanting microglia/macrophages ([@b112-btt-2-253]; [@b115-btt-2-253]). Another beneficial role of microglia may be phagocytosis. As mentioned above, myelin-related protein is one of the key factors that inhibit regeneration. Microglia can phagocytose the myelin debris after CNS injury but not speedily and sufficiently ([@b49-btt-2-253]; [@b19-btt-2-253]). Thus, promoting the phagocytic ability may be one of the strategies that can be employed for therapy ([@b146-btt-2-253]). Transplantation of macrophages that are prestimulated by peripheral nerves (myelin components) into injured site promotes the recovery of motor function ([@b116-btt-2-253]). Although it is not clear whether this beneficial effect is due to the enhancement of phagocytic ability, one can deduce that in some way, an appropriate activation of microglia/macrophage targeted to autologous tissue (possibly myelin) is protective and effective in repair and regeneration (for review, [@b129-btt-2-253]). In the developing brain, microglia infiltrate into the CNS around E10 in rodents and are believed to play a role in engulfing the dying apoptotic cells ([@b2-btt-2-253]). Interestingly, microglial cells express neurotrophic factors even in the developing brain ([@b38-btt-2-253]), and it is assumed that these cells may have some role to play in axonal growth ([@b25-btt-2-253]; [@b139-btt-2-253]), although a direct *in vivo* evidence is deficient. In this case, understanding the role of microglia in the injured brain may offer an important clue regarding its role in development.

Plasticity in development, and adult brain injuries
===================================================

It is known that after SCI, compensatory axonal sprouting occurs in the upper level of the lesion ([Figure 1](#f1-btt-2-253){ref-type="fig"}; [@b1-btt-2-253]; [@b87-btt-2-253]; [@b153-btt-2-253]; [@b44-btt-2-253]). For a long time, the reason behind the occurrence of slight functional recovery, unless spinal axons regenerate, was unclear; however, Bareyre et al suggested that the new sprouting axons in the upper level establish a new contact with the intraspinal interneurons and form a new neural circuit that may contribute to partial recovery ([@b6-btt-2-253]). Interestingly, the temporal pattern of the newly generated sprouting appears to be significantly similar to the developmental process of CST. As described above, axons in the CST are elongated in early postnatal life, and after some "waiting period" (approximately 3 days), passing axons start establishing collaterals; in other words, they begin sprouting (O'Leary and Terashima 1988; [@b50-btt-2-253]; [@b68-btt-2-253]). Thus, an understanding of the mechanism of collateral formation in the developing brain will lead us to a new approach for promoting sprouting that may lead to functional recovery after SCI. In the developing brain, axonal collateral formation appears to be initiated by diffusible factors that emanate from their targets ([@b121-btt-2-253]; [@b70-btt-2-253]). Although the cues that induce collateral formation in the spinal cord are unidentified, a potential cue may be neurotrophic factors. NT-3 and BDNF are known to promote axonal branching in a variety of neurons. Indeed, NT-3 enhances developmental sprouting in the spinal cord, and also in the injured adult spinal cord ([@b124-btt-2-253]; [@b54-btt-2-253]; [@b164-btt-2-253]). Although some recent papers reveal contrasting results on NT-3, and propound instead that providing BDNF treatment to the cell body of CST promotes sprouting ([@b59-btt-2-253]; [@b55-btt-2-253]; [@b148-btt-2-253]).

Interestingly, similar factors appear to be used for controlling the developmental plasticity and plasticity after adult brain injury. Neural activity is the first factor that influences the plastic changes. Developing visual cortex is one of the extensively studied areas regarding plasticity in development. Neural inputs from both eyes through the thalamus compete with each other in the developing visual cortex through neural activity. This competition normally forms specific ocular dominance columns in the visual cortex that respond to alternative eyes. Intriguingly, monocular deprivation during the critical period, which is the window period during early postnatal days when plastic changes can occur, shifts the response of neurons in both columns toward the dominantly activated input from the opened eye (for review, [@b58-btt-2-253]). Thus, neural activity appears to be the first step in inducing plasticity. In the case of SCI, many reports have indicated that rehabilitation -- such as locomotor training and environmental enrichment, which supposedly enhance neural activity -- promotes functional recovery in rodents ([@b82-btt-2-253]; [@b147-btt-2-253]; [@b63-btt-2-253]; [@b39-btt-2-253]). The mechanisms that improve function after rehabilitation are not fully understood; however, neural plasticity must be involved.

Neurotrophin is the next factor involved in plasticity. In the developing visual cortex, excess treatment or removal of BDNF, NT-4/5 prevents or delays ocular dominance formation ([@b21-btt-2-253], [@b22-btt-2-253]), and focal injection of NT-4/5 prevents the plastic shift in the visual cortex ([@b119-btt-2-253]). This implies that axons from each eye compete with each other through limited amount of neurotrophins in an activity-dependent manner, and only the ones that can receive neurotrophic factors are stabilized. In the SCI, neurotrophic factors appear to enhance plastic changes via sprouting, as mentioned above. Thus, the precise treatment using neurotrophic factors and stimulation of neural activity (it is related to good rehabilitation strategies) should be one of the key strategies to enhance plasticity after SCI.

The last factor contributing to plasticity is inhibitory molecules. The increasing number of inhibitory factors during postnatal development appears to terminate or decrease the overall plasticity of neural connections. CSPGs that inhibit regeneration after SCI are one of the inhibitory factors that also decrease plasticity through the developing brain. CSPGs organize a perineuronal net as the extracellular matrix. Treatment using chondroitinase ABC degrades CSPGs and reactivates the plasticity toward monocular deprivation in the adult visual cortex ([@b108-btt-2-253]). Interestingly, increasing myelin formation also appears to terminate the plastic changes in the visual cortex of younger brain. It is reported that the critical period is delayed in the visual cortex of NgR deficient mice ([@b94-btt-2-253]). As observed in younger animals, myelin components also inhibit plasticity after adult brain injury. For example, in Nogo--/-- and NgR--/-- mice, sprouting (plasticity) of axons was promoted after CNS injury ([@b83-btt-2-253]; [@b23-btt-2-253]), and blocking NgR signals also enhanced sprouting rostral to the lesion site after SCI ([@b85-btt-2-253], [@b86-btt-2-253]; [@b84-btt-2-253]).

In conclusion, all these instances suggest that plasticity of axons in the developing brain and adult brain after the injury appear to involve similar mechanisms. Thus, understanding the mechanism of plasticity during development will offer an important clue for developing a new therapeutic strategy for SCI by promoting plasticity.

Strategy for therapy: insights from guidance molecules
======================================================

The last insights obtained from the researches on development are that a number of axonal guidance molecules guiding axons during development are re-expressed by the glial and inflammatory cells after the injury or continuously expressed in adult CNS cells. By now, Netrin1 ([@b152-btt-2-253]), EphA4 ([@b52-btt-2-253]), EphB2 ([@b18-btt-2-253]), Sema3, 7a ([@b31-btt-2-253]; [@b106-btt-2-253]), and Slit1, 3 ([@b152-btt-2-253]) have been revealed to be expressed in the lesion site of SCI. Although these molecules have various roles in the repair process, such as activation of astrocytes (EphA4; [@b52-btt-2-253]), scar formation (EphB2; [@b18-btt-2-253]), and migration of adult progenitor cells (Netrin1; [@b107-btt-2-253]), there are no doubts that some of these molecules also affect the outgrowth of injured axons. Sema3A is expressed mainly in the fibroblasts after injury ([@b31-btt-2-253]), and the specific inhibitor of Sema3A clearly promotes the regeneration of axons ([@b73-btt-2-253]). We also demonstrated an additional example. Repulsive guidance Molecule (RGM), a glycosylphosphatidylinositol (GPI)-anchored membrane-bound protein, is another family of guidance molecules important for axonal development, which had been shown to navigate the optic nerve in the chick tectum to form a topographic map ([@b137-btt-2-253]; [@b98-btt-2-253]; for review, [@b158-btt-2-253]). We as well as others elucidated that RGMa is also expressed in the injured tissue including astrocytes, microglia, oligodendrocytes, and neurons ([@b127-btt-2-253]; [@b57-btt-2-253]). Treatment with RGMa antibody after the SCI in a rat promotes axonal regeneration and synapse formation, and recovers behavioral function, as evaluated by BBB test ([@b57-btt-2-253]; [@b80-btt-2-253]). This data suggests that RGMa is one of the key inhibitory factors for axonal regeneration. Morphogens are also candidate molecules that inhibit regeneration. We have recently reported that BMP-2/4 expression is elevated in the lesion of SCI and administration of Noggin, a soluble BMP antagonist, promotes regeneration of CST ([@b93-btt-2-253]). BMP is known as a repulsive guidance molecule to commissural axons in the developing spinal cord ([@b3-btt-2-253]; [@b20-btt-2-253]), suggesting that similar repulsive factors re-expressed in the adult lesion site.

One important issue is that the spinal cord has various descending and ascending axons and these have different regenerative reaction to therapeutic approaches ([@b33-btt-2-253]). In the developing brain, axons in each axon tract have different set of receptors for guidance molecules to select specific route for the targets. It appears that each tract in adult also has specific molecular profiles for regeneration. For example, treatment of Sema3A-inhibitor promotes regeneration of raphespinal tract but not CST ([@b73-btt-2-253]). It was shown that raphespinal axons express neuropilin-1, the receptor to mediate repulsive effect of Sema3A. Netrin-1 is expressed in oligodendrocytes, cells of central canal, and the meninges in adult SCI, and inhibits axonal growth through the receptor, Unc5 ([@b92-btt-2-253]). Implantation of Netrin-1 expressing fibroblasts inhibits the regeneration of rubrospinal fibers which express Unc5A, but not CGRP-positive nociceptive axons which do not express Unc5. Thus, when the effects of the treatment are examined, we should consider which axons express receptors for guidance molecules, which axons regenerate after treatments, and how the regeneration of specific axons contribute to behavioral appearance.

Other targets are the downstream signaling molecules of inhibitory cues. Recent reports indicate that the small GTP-binding protein Rho and its effectors, ie, ROCK, are the key molecules that mediate inhibitory signals for axonal growth (for review see [@b100-btt-2-253]; [@b78-btt-2-253]). Importantly, Rho is a common downstream molecule of many repulsive cues, including RGM ([@b57-btt-2-253]), myelin-associated proteins through p75 ([@b156-btt-2-253]), CSPGs ([@b99-btt-2-253]), and members of the Semaphorin and Ephrin families ([@b149-btt-2-253]; [@b140-btt-2-253]). Thus, inhibiting the common pathway that mediates repulsion is one of the promising targets for therapy. Indeed, treatment with ROCK inhibitors, promotes axonal regeneration after SCI ([@b32-btt-2-253]; [@b47-btt-2-253]; [@b142-btt-2-253]). Understanding the detailed molecular mechanism of the inhibitory signals will reveal new targets for therapy.

Many discoveries regarding the role of various molecules and their effects in the case of SCI have emerged. This indicates that multiple inhibitory factors suppress regeneration. In fact, regeneration can be achieved but not to a great extent in each report. The approaches therefore shift to the use of a combination of several therapeutic approaches. For example, treatment with NT3 and an antibody of myelin-associated inhibitory proteins (IN-1) ([@b124-btt-2-253]), transplantation of fetal spinal cord and neurotrophic factors ([@b17-btt-2-253]), chondroitinase ABC and cellular transplantation ([@b45-btt-2-253]) etc have succeeded in promoting regeneration to a much greater extent than individual therapeutic approaches. Overall, combinational strategies that promote the completion of the repair process including inflammation and scar formation rapidly and in a compact manner, excluding the inhibitory factors for regeneration, bridging the lesion site, and facilitating the regeneration and sprouting of axons, should be considered for designing new therapeutic approaches. As the number of possible combinations that should be tested is already very large, greater efforts will be required to establish appropriate therapeutic methods. The scientific community working on SCI therefore needs to be increased and collaborate with each other. Furthermore, developmental neuroscientists can rightly contribute to this community.

In conclusion, an important aspect gathered from a large number of studies is that behavioral recovery after the injury by various treatments and methods is well correlated with the histological changes that occur in axons, ie axonal regeneration and sprouting. This implies that axonal regeneration and sprouting are crucial for behavioral recovery. Thus, promoting axonal elongation and sprouting is now one of the most important strategies to be employed for developing a new therapeutic method. In this case, basic research on brain development will reveal important clues.

![Comparison between the environments of a developing brain and an adult brain after SCI. **A:** Axons (blue line; in this case, CST) projected up to a long distance through a specific route. Even after the injury (red), axons can regenerate more extensively than in adults. Compensatory sprouting also occurs with high plastic ability (orange arrow). **B:** In the adult brain, axons (green line; in this case, CST) cannot regenerate after the injury (red), but compensatory sprouting occur in the rostral positions (orange arrows); however, the extent to which this occurs is not greater than that in the developing brain. **C:** Different components and their properties involved in the developing and adult brains after the SCI. Each function is represented as the role toward axonal outgrowth (regeneration) and sprouting (plasticity). The properties of the components are presented within the parentheses. The strategies for the therapy targeting each component are represented in the right column. The details can be found in the text.](btt-2-253f1){#f1-btt-2-253}
